Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: fenclofenac, meloxicam, dexketoprofen +76 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 32 Parkinson's papers of 4,585 | 0.54 |
| pathways Reactome | 8 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2357
Sealed predictions
- PTGS2 in dopamine neurons, braak+0.30 (p 0.430) → +0.14 (p 0.725)receipt 2365
Swarm cases
receipt 2365: PTGS2 in dopamine neurons, braak
- power
- full sample +0.22 (p 0.374, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.573, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.573, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.40, sign flips 0; without severely affected donors +0.22 (p 0.374, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PTGS2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts